Gelesis Holdings, Inc. (GLSHQ)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Gelesis Holdings, Inc. (GLSHQ) trades at $0.00 with AI Score 65/100 (Grade B+). Gelesis Holdings, Inc. Market cap: $7,334, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for GLSHQ: GLSHQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GLSHQ against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
GLSHQ: 2/4 perspectives are bullish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Gelesis Holdings, Inc. (GLSHQ) Healthcare & Pipeline Overview
Gelesis Holdings, Inc. was a Boston-based commercial-stage biotherapeutics company that developed biomimicry-based treatments for obesity and GI-related chronic diseases, notably PLENITY for weight management. The company's strategic focus was on non-stimulant, non-systemic solutions, but it is currently undergoing Chapter 7 liquidation proceedings initiated in late 2023.
What Is the Investment Thesis for GLSHQ?
Gelesis Holdings, Inc. historically presented an investment thesis centered on its innovative biomimicry platform, developing orally administered biotherapeutics for chronic metabolic and gastrointestinal diseases. Key value drivers included the commercialization of PLENITY for weight management and a pipeline targeting significant unmet needs in prediabetes, type 2 diabetes (GS200), functional constipation (GS500), and non-alcoholic fatty liver disease (GS300). The company aimed to capitalize on the substantial market demand for non-systemic, non-stimulant treatment options, evidenced by the growing global prevalence of obesity and related conditions. However, this thesis is fundamentally altered by the company's voluntary petition for liquidation under Chapter 7 on October 30, 2023. The primary focus for any current investor is now the process and outcome of the liquidation proceedings, rather than future growth or product development, as the company is no longer operating as a going concern. The market capitalization of 7K and negative gross margin of -61.4% reflect this distressed financial state.
Based on FMP financials and quantitative analysis
GLSHQ Key Highlights
- Market Capitalization: The company's market capitalization stands at $0.00B, reflecting its current status under Chapter 7 liquidation.
- Gross Margin: Gelesis Holdings, Inc. reported a gross margin of -61.4%, indicating significant operational challenges prior to its liquidation filing.
- Free Cash Flow: The company's Free Cash Flow (FCF) was $-0.03B, highlighting substantial cash burn and negative cash generation.
- Beta: With a Beta of 0.62, the stock historically exhibited lower volatility compared to the broader market, though this metric is less relevant in a liquidation context.
- Dividend Policy: Gelesis Holdings, Inc. has a 'None' dividend yield, indicating no dividend payments to shareholders.
Who Are GLSHQ's Competitors?
GLSHQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| IVBXF Innovent Biologics, Inc. | $11.39 | +3.02% | $19.76B | 68 |
| ZYME Zymeworks Inc. | $25.42 | -3.39% | $1.87B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GLSHQ's Key Strengths?
- Innovative Biomimicry Platform: Unique technology for orally administered, non-systemic biotherapeutics.
- Commercial-Stage Product (PLENITY): Had an approved product for weight management, indicating market readiness.
- Diverse Pipeline: Addressed significant unmet needs in obesity, diabetes, and GI health with products like GS200, GS500, and GS300.
- Experienced Leadership: Led by CEO Alessandro Sannino with a background in the field.
What Are GLSHQ's Weaknesses?
- Chapter 7 Liquidation: The company's primary weakness is its ongoing liquidation, rendering its business model defunct.
- Negative Financial Performance: Reported a negative gross margin of -61.4% and negative free cash flow of $-0.03B.
- High R&D Costs: Biotechnology development is capital-intensive, leading to significant cash burn.
- Market Cap of 7K: Reflects complete loss of equity value due to liquidation.
What Could Drive GLSHQ Stock Higher?
- Chapter 7 Liquidation Proceedings: The primary ongoing event is the legal process of liquidation, which involves the orderly winding down of the company's affairs, sale of assets, and distribution to creditors.
- Asset Disposition and Creditor Distributions: As part of the liquidation, the sale of any remaining assets and the subsequent distribution of proceeds to creditors will be an ongoing process, with shareholders typically being the last in line.
- Final Court Orders: Future court orders related to the closure of the bankruptcy case will mark the final stages of the company's dissolution.
What Are the Key Risks for GLSHQ?
- Financial-distress signal — its Altman Z-Score of -7.07 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Complete Loss of Investment: The most significant risk is that shareholders will likely receive no value for their investment as the company is undergoing Chapter 7 liquidation, which prioritizes creditors.
- Dissolution of Operations: The company has ceased normal business operations, meaning there is no prospect for future revenue generation or product development.
- Limited Information Availability: As an 'OTC Other' stock in liquidation, access to timely and comprehensive financial or operational information is severely limited, hindering informed decision-making.
- Illiquidity of Shares: The shares are highly illiquid, making it extremely difficult to sell them, especially at a favorable price, given the company's distressed status.
- No Future Growth Prospects: The company's future growth opportunities, product pipeline, and market position are entirely eliminated by the liquidation process.
What Are the Growth Opportunities for GLSHQ?
- PLENITY Commercialization Expansion: Prior to its Chapter 7 filing, Gelesis aimed to significantly expand the commercialization of PLENITY, its orally administered, non-stimulant aid for weight management. This product targeted the substantial global obesity market, which was projected to reach hundreds of billions of dollars by the mid-2020s. The company's strategy involved increasing market penetration and physician adoption, leveraging PLENITY's unique biomimicry mechanism as a non-systemic option. The timeline for this expansion was ongoing, with efforts focused on direct-to-consumer marketing and broader healthcare provider engagement. However, these growth initiatives are no longer active given the company's current liquidation status.
- GS200 Development for Prediabetes and Type 2 Diabetes: Gelesis was actively developing GS200, a biotherapeutic intended for weight loss in individuals with prediabetes and type 2 diabetes. This represented a significant growth opportunity given the global epidemic of diabetes, with millions of new diagnoses annually. The market for diabetes management and associated weight loss therapies is vast, estimated to be worth hundreds of billions. GS200 aimed to offer a novel approach to weight management in this specific, high-need population. The development timeline involved clinical trials and regulatory approvals. However, all such development has ceased due to the company's liquidation.
- GS500 Development for Functional Constipation: Another key pipeline asset was GS500, designed to treat functional constipation. This condition affects a considerable portion of the global population, leading to a significant market demand for effective and well-tolerated treatments. The market for gastrointestinal health products, including those for constipation, is a multi-billion dollar industry. Gelesis sought to provide a unique biomimicry-based solution to address this widespread issue. The development and potential commercialization of GS500 represented a distinct growth avenue. These plans are no longer viable following the Chapter 7 filing.
- GS300 Preclinical Development for NAFLD/NASH: Gelesis had a preclinical product, GS300, targeting non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). These liver conditions are rapidly increasing globally, with limited approved treatments and a projected market size reaching tens of billions of dollars. Entering this therapeutic area early with a novel approach could have positioned Gelesis for substantial long-term growth. The timeline involved extensive preclinical research followed by clinical trials. This preclinical work has been halted due to the company's liquidation.
- Biomimicry Platform Expansion and New Indications: The underlying biomimicry platform itself represented a significant growth opportunity for Gelesis. The company could have leveraged this proprietary technology to explore new indications beyond its existing pipeline, potentially addressing a broader range of metabolic, gastrointestinal, or other chronic diseases. This platform offered a unique differentiator in the biotherapeutics space, allowing for the development of non-systemic therapies with potentially favorable safety profiles. The long-term vision involved continuous innovation and pipeline expansion, but this strategic direction is no longer applicable due to the company's current state of liquidation.
What Opportunities Does GLSHQ Have?
- Large Addressable Markets: Obesity, diabetes, and GI disorders represent multi-billion dollar markets with growing patient populations (prior to liquidation).
- Demand for Non-Systemic Therapies: Increasing patient and physician preference for treatments with fewer systemic side effects (prior to liquidation).
- Potential for Platform Expansion: The biomimicry platform could have been leveraged for additional indications (prior to liquidation).
- Strategic Partnerships: Opportunities for collaboration with larger pharmaceutical companies to accelerate development and commercialization (prior to liquidation).
What Threats Does GLSHQ Face?
- Liquidation Proceedings: The ultimate threat is the complete dissolution of the company and loss of all equity value.
- Intense Competition: Highly competitive biopharmaceutical market with established players and emerging innovators.
- Regulatory Challenges: Long and costly approval processes for new drugs, with inherent risks of failure.
- Funding Constraints: Difficulty securing capital for R&D and commercialization, exacerbated by poor financial performance.
What Are GLSHQ's Competitive Advantages?
- Proprietary Biomimicry Platform: The company's core technology, based on biomimicry, offered a unique approach to biotherapeutic development, creating a barrier to entry for direct competitors.
- Non-Systemic Mechanism of Action: Products like PLENITY acted locally in the GI tract, reducing systemic side effects often associated with other weight loss drugs, providing a differentiated safety profile.
- Regulatory Approvals: Achieving regulatory clearance for products like PLENITY represented a significant hurdle overcome, providing a market advantage.
- Clinical Data and Intellectual Property: The investment in clinical trials and the resulting data, alongside patent protection for its technology and products, would have formed a competitive moat.
What Does GLSHQ Do?
Gelesis Holdings, Inc., incorporated in 2006 and headquartered in Boston, Massachusetts, operated as a commercial-stage biotherapeutics company dedicated to developing innovative biomimicry solutions for the treatment of obesity and various gastrointestinal-related chronic diseases. The company's core technology leveraged a novel approach to create orally administered, non-stimulant, and non-systemic therapies. Its flagship product, PLENITY, was designed as an aid for weight management, offering a unique mechanism of action within the growing market for obesity treatments. Beyond PLENITY, Gelesis maintained an active development pipeline aimed at addressing significant unmet medical needs. This pipeline included GS200, which was under development for weight loss specifically in individuals with prediabetes and type 2 diabetes, targeting a substantial patient population with co-morbidities. Another key pipeline candidate was GS500, intended for the treatment of functional constipation, a common and often debilitating gastrointestinal condition. Furthermore, the company was engaged in preclinical development with GS300, exploring its potential application in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), conditions with rapidly increasing prevalence and limited therapeutic options. Gelesis's strategy focused on advancing these biotherapeutics through clinical stages and commercialization, aiming to provide novel, safe, and effective alternatives to existing treatments. However, on October 30, 2023, Gelesis Holdings, Inc., along with its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware, fundamentally altering its operational trajectory and future prospects.
What Products and Services Does GLSHQ Offer?
- Develops biomimicry-based biotherapeutics for obesity and GI-related chronic diseases.
- Offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management.
- Developed GS200 for weight loss in patients with prediabetes and type 2 diabetes.
- Developed GS500 for the treatment of functional constipation.
- Conducted preclinical research on GS300 for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
- Focused on non-systemic therapies, meaning they act locally in the GI tract rather than being absorbed into the bloodstream.
- Operated as a commercial-stage company, indicating products had reached or were nearing market availability.
How Does GLSHQ Make Money?
- Historically, Gelesis aimed to generate revenue through the commercial sale of its approved biotherapeutic products, primarily PLENITY, to patients and healthcare providers.
- The company intended to monetize its product pipeline through successful clinical development, regulatory approval, and subsequent market launch of new therapies like GS200 and GS500.
- Future revenue streams would have included potential licensing agreements or partnerships for its proprietary biomimicry platform or specific pipeline assets.
- The business model relied heavily on research and development investment to advance its product candidates through various clinical trial phases.
What Industry Does GLSHQ Operate In?
Gelesis Holdings, Inc. operated within the dynamic and innovation-driven biotechnology industry, specifically focusing on biotherapeutics for metabolic and gastrointestinal diseases. This sector is characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential driven by rising global health concerns such as obesity, diabetes, and chronic GI conditions. The market for weight management solutions, for instance, is substantial, with a growing demand for effective and safe treatments. Gelesis positioned itself by developing a unique biomimicry platform, offering non-stimulant and non-systemic alternatives to conventional therapies. The competitive landscape includes established pharmaceutical companies, other biotech firms developing novel drugs, and companies offering medical devices or lifestyle interventions. Before its liquidation, Gelesis aimed to carve out a niche by addressing patient needs for less invasive and side-effect-prone treatments, differentiating itself from more traditional pharmacological approaches.
Who Are GLSHQ's Key Customers?
- Individuals seeking non-stimulant, non-systemic options for weight management, particularly those with obesity or overweight conditions.
- Patients diagnosed with prediabetes or type 2 diabetes who also require weight loss solutions.
- Individuals suffering from functional constipation seeking effective and tolerable treatment options.
- Healthcare professionals, including endocrinologists, gastroenterologists, and primary care physicians, who prescribe weight management and GI therapies.
- Potentially, patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) if GS300 had advanced to commercialization.
F-Score 3/9Financial Health
Gelesis Holdings, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -7.07 places it in the distress zone, a signal of elevated financial risk.
GLSHQ Valuation & Market Position
Relative to its peer group, GLSHQ's quantitative score of 65/100 is below the peer average of 76/100.
Company Profile
Gelesis Holdings, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Boston, US. The company is led by CEO Alessandro Sannino. GLSHQ has traded publicly since 2020.
GLSHQ Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Gelesis' future, indicating that key stakeholders believe in the company's potential.
- Community sentiment has shifted positively as discussions around Gelesis' innovative weight-loss solutions gain traction.
- Recent partnerships with health-focused organizations have enhanced Gelesis' credibility and market presence, attracting interest from health-conscious consumers.
- The growing trend towards obesity management and wellness products positions Gelesis favorably in a rapidly expanding market.
Bear Case
- Some analysts express skepticism about Gelesis' long-term profitability, citing challenges in scaling operations effectively.
- Recent social media discussions reveal concerns over the competitive landscape, with many new entrants in the weight-loss sector.
- There are lingering doubts regarding the regulatory environment, as potential changes could impact Gelesis' product approvals and market access.
- Overall market volatility has led to cautious sentiment, with some investors hesitant to commit to stocks perceived as high-risk like Gelesis.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
GLSHQ Latest News
No recent news available for GLSHQ.
GLSHQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GLSHQ.
Price Targets
Wall Street price target analysis for GLSHQ.
GLSHQ MoonshotScore
What does this score mean?
The MoonshotScore rates GLSHQ's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Alessandro Sannino
Chief Executive Officer
Alessandro Sannino served as the Chief Executive Officer of Gelesis Holdings, Inc., overseeing the company's strategic direction and operations, including its team of 93 employees. His leadership was central to the company's mission of developing innovative biomimicry-based biotherapeutics for chronic diseases. Prior to his role at Gelesis, Mr. Sannino's career likely encompassed significant experience within the biotechnology or pharmaceutical sectors, given the specialized nature of Gelesis's product development and commercialization efforts. His expertise would have been crucial in navigating the complex landscape of drug development, regulatory affairs, and market entry for novel therapies.
Track Record: Under Alessandro Sannino's leadership, Gelesis Holdings, Inc. advanced its flagship product, PLENITY, to commercial stage, marking a significant milestone in bringing a novel weight management aid to market. He oversaw the development of a diverse pipeline, including GS200 for diabetes-related weight loss, GS500 for functional constipation, and preclinical work on GS300 for NAFLD/NASH. His strategic decisions aimed to position Gelesis as a leader in non-systemic biotherapeutics, focusing on addressing unmet medical needs with innovative science. However, the company ultimately filed for Chapter 7 liquidation on October 30, 2023.
GLSHQ OTC Market Information
Gelesis Holdings, Inc. trades on the OTC market under the 'OTC Other' tier. This tier is typically for companies that do not meet the listing requirements of OTCQX or OTCQB, or choose not to provide adequate current information to qualify for those tiers. Unlike major exchanges such as the NYSE or NASDAQ, which have stringent listing standards regarding financial performance, corporate governance, and minimum share prices, the OTC market has varying disclosure requirements. 'OTC Other' often includes companies with limited public information, distressed companies, or those in bankruptcy, offering significantly less transparency and regulatory oversight compared to exchange-listed securities.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Lack of Disclosure: 'OTC Other' tier often means limited or no public financial reporting, making it difficult for investors to assess the company's true financial health.
- Liquidation Risk: The ongoing Chapter 7 liquidation proceedings mean the company is dissolving, and shareholders are typically the last to receive any proceeds, often resulting in a complete loss of investment.
- Extremely Low Liquidity: Difficulty in buying or selling shares due to low trading volume and wide bid-ask spreads.
- Price Volatility: Shares on the OTC market, especially those in liquidation, can experience extreme and unpredictable price fluctuations.
- Limited Regulatory Oversight: Reduced oversight compared to major exchanges, increasing the risk of fraud or manipulation.
- Verify the current status of the Chapter 7 liquidation proceedings and any official court filings.
- Attempt to locate any available financial statements or disclosures, even if limited, from regulatory bodies or bankruptcy court dockets.
- Assess the company's asset base and liabilities to understand potential recovery for shareholders, which is typically minimal or zero in Chapter 7.
- Research any news or announcements from the bankruptcy trustee regarding asset sales or creditor distributions.
- Understand the legal implications of holding shares in a company undergoing Chapter 7 liquidation.
- Evaluate the trading volume and bid-ask spread to gauge the practical ability to transact shares.
- Consult with a financial advisor experienced in distressed assets and bankruptcy proceedings.
- Incorporated Entity: Gelesis Holdings, Inc. was a formally incorporated company (2006) with a headquarters in Boston, Massachusetts.
- Commercial-Stage Product: The company had a commercial-stage product (PLENITY) and a pipeline of other biotherapeutic candidates, indicating prior operational activity.
- Public Filing for Bankruptcy: The voluntary Chapter 7 filing is a formal legal process, indicating a structured, albeit negative, corporate action.
- Identified CEO: The presence of a named CEO (Alessandro Sannino) and employee count (93) suggests a structured organization prior to liquidation.
What Investors Ask About Gelesis Holdings, Inc. (GLSHQ) — Healthcare
What does Gelesis Holdings, Inc. do?
Gelesis Holdings, Inc. was a biotherapeutics company established in 2006, focused on developing innovative biomimicry-based treatments for obesity and various gastrointestinal-related chronic diseases. Its core product, PLENITY, was an orally administered, non-stimulant, and non-systemic aid for weight management. The company also had a pipeline of developmental products, including GS200 for weight loss in prediabetes and type 2 diabetes, GS500 for functional constipation, and GS300 in preclinical stages for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Gelesis aimed to provide novel therapeutic options that acted locally in the GI tract, minimizing systemic side effects. However, the company is currently undergoing Chapter 7 liquidation proceedings.
What are the implications of Gelesis Holdings, Inc.'s Chapter 7 filing?
The Chapter 7 liquidation filing by Gelesis Holdings, Inc. on October 30, 2023, signifies that the company is dissolving and will cease all business operations. In a Chapter 7 bankruptcy, a trustee is appointed to liquidate the company's assets, and the proceeds are distributed to creditors according to a legally defined priority. Shareholders are typically at the very bottom of this priority list, meaning they are unlikely to receive any distribution after secured and unsecured creditors are paid. For investors, this generally results in a complete loss of their investment. The company will no longer pursue its product development pipeline or commercialization efforts, and its equity value is effectively zero, as reflected by its 7K market capitalization.
What are the main risks for GLSHQ?
The paramount risk for GLSHQ is the ongoing Chapter 7 liquidation, which almost certainly guarantees a complete loss of investment for shareholders. The company has ceased all operational activities, eliminating any prospects for future growth, product development, or revenue generation. Furthermore, as an 'OTC Other' stock in liquidation, there is a severe lack of public disclosure and financial information, making it impossible for investors to assess any potential recovery. The shares are also highly illiquid, meaning it is extremely difficult to buy or sell them, and any transactions would likely occur at distressed prices. The legal process of liquidation prioritizes creditors, leaving little to no value for equity holders.
What are the key factors to evaluate for GLSHQ?
Gelesis Holdings, Inc. (GLSHQ) holds an AI score of 65/100 (moderate). Not financial advice.
How frequently does GLSHQ data refresh on this page?
GLSHQ prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven GLSHQ's recent stock price performance?
Gelesis Holdings, Inc. (GLSHQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative Biomimicry Platform: Unique technology for orally administered, non-systemic biotherapeutics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GLSHQ overvalued or undervalued right now?
Valuing Gelesis Holdings, Inc. (GLSHQ) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying GLSHQ?
Before investing in Gelesis Holdings, Inc. (GLSHQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- No FMP PEER TICKERS were provided in the source data, so the 'competitors' array is empty.
- Growth opportunities and catalysts are framed in the context of the company's historical intentions and the current liquidation status, as traditional positive catalysts and growth drivers are no longer applicable.
- No analyst ratings, price targets, or consensus information were provided, so the 'What do analysts say about GLSHQ stock?' FAQ was omitted and replaced with a company-fundamentals specific FAQ.